Abstract: While the incidence of endometrial cancer continues to rise, the therapeutic options remain limited for advanced or recurrent cases, and most cases are resistant to therapy. The anti-tumor effect of many chemotherapeutic drugs and radiotherapy depends on the induction of DNA damage in cancer cells; thus, activation of DNA damage response (DDR) pathways is considered an important factor affecting resistance to therapy. When some DDR pathways are inactivated, inhibition of other DDR pathways can induce cancer-specific synthetic lethality. Therefore, DDR pathways are considered as promising candidates for molecular-targeted therapy for cancer. The crosstalking ataxia telangiectasia mutated and Rad3 related and checkpoint kinase 1 (ATR-Chk1) and ataxia telangiectasia mutated and Rad3 related and checkpoint kinase 2 (ATM-Chk2) pathways are the main pathways of DNA damage response. In this study, we investigated the anti-tumor effect of inhibitors of these pathways in vitro by assessing the effect of the combination of ATM or ATR inhibitors and conventional DNA-damaging therapy (doxorubicin (DXR), cisplatin (CDDP), and irradiation) on endometrial cancer cells. Both the inhibitors enhanced the sensitivity of cells to DXR, CDDP, and irradiation. Moreover, the combination of ATR and Chk1 inhibitors induced DNA damage in endometrial cancer cells and inhibited cell proliferation synergistically. Therefore, these molecular therapies targeting DNA damage response pathways are promising new treatment strategies for endometrial cancer.

Keywords: DNA damage response (DDR) pathways; ATR-Chk1 pathway; ATM-Chk2 pathway; combination therapy; molecular-targeted therapies
accounts for 80% of the endometrial cancer cases. Poorly differentiated endometrioid carcinoma, serous carcinoma, clear-cell carcinoma, and undifferentiated carcinoma are less frequent, and classified as type 2 [2]. The carcinogenesis of type 1 endometrial cancer is related to a continuous exposure to estrogen, e.g., early menarche, late menopause, nulliparous, hormone replacement therapy, obesity, hypertension, and diabetes [3–5]. Although the peak age of onset range is 50–60 years, the incidence of endometrial cancer has been rising in all age groups [6]. The standard treatment of endometrial cancer consists of surgery followed by radiation therapy, chemotherapy, or both, depending on the risk factors of a patient, which include muscle layer invasion, vascular invasion, grade, lymph node metastasis, and the stage of the disease [7–10]. Doxorubicin (DXR) and cisplatin (CDDP) are the most commonly used chemotherapeutics. Nonetheless, 10–15% of the cases without adjuvant therapy have a recurrence of cancer. The prognosis for recurrent cases is very poor, with a 5-year survival rate of approximately 15% because of the limited choices of treatment and resistance to therapy. Therefore, molecular-targeted therapy is expected to be the new strategy for endometrial cancer treatment [11,12].

DNA damage response (DDR) proteins are activated or inactivated in various types of cancer [13]. The anti-tumor effect of many chemotherapeutic drugs and radiotherapy depends on the induction of DNA damage to cancer cells, for example, DXR increases double-strand breaks through inhibition of topoisomerase II, CDDP causes DNA crosslinks and nucleotide excision repair, and irradiation induces DNA damage directly. The activation of DDR proteins in cancer cells is regarded as one of the most important factors of resistance to therapy [14]. On the other hand, in case some of the DDR pathways are inactivated, cancer cells may depend more highly on another DDR pathway, and inhibiting the other DDR pathway can induce cancer-specific synthetic lethality [15–17]. Therefore, DDR pathways are considered as promising candidates for molecular-targeted therapy.

Additionally, endometrial cancer cells can be in a state of genomic instability with replication stress through loss of Phosphatase and tensin homolog (PTEN) or Ras mutations. Endometrial cancer cells may survive such instability by activating DDR pathways, therefore molecular therapy targeting the DDR pathway may be highly effective [18]. ATR (ATM and Rad3-related) and ATM (ataxia telangietasia-mutated) proteins are members of the PIKK (PI3K-like protein kinase) family, which are autophosphorylated and activated by DNA damage; then, they induce phosphorylation of its downstream target, such as Chk1 (checkpoint kinase 1) or Chk2 (checkpoint kinase 2), and regulate cell cycle and DNA repair. ATR is known as the gene responsible for Seckel syndrome, a rare disorder that typically results in short stature (dwarfism) [19]. ATR mainly reacts to ultraviolet light or a single-strand DNA generated by a DNA replication disorder, and subsequently undergoes autophosphorylation, induces phosphorylation of its downstream target Chk1, and regulates cell cycle [20,21]. Meanwhile, ATM was identified as the responsible gene of ataxia telangietasia, a hereditary disease characterized by cancer predisposition [22]. ATM mainly reacts to DNA double-strand breaks and, like ATR, it then induces autophosphorylation and phosphorylation of Chk2 and p53, and regulates cell cycle [20,21]. ATR-Chk1 and ATM-Chk2 pathways mutually crosstalk [23]. Clinical trials are now ongoing to evaluate the use of inhibitors of these pathways in some types of cancers [24]. Regarding the effect of ATR inhibitors and ATM inhibitors in endometrial cancer, the ATR inhibitor ETP46464 enhances the anti-tumor effect of CDDP in endometrial cancer cells, but the ATM inhibitor KU55933 does not, while both the inhibitors enhance the effect of irradiation [25]. There is no previous report about the effect of inhibitors of these pathways combined with DXR. The ATM-Chk2 pathway frequently has mutations or decreased expression, not only in hereditary cases, but also in many types of cancers, such as endometrial cancer, breast cancer, pancreas cancer, head and neck squamous cell cancer, and non-small-cell lung cancer. Thus, inhibiting the ATR-Chk1 pathway may induce cancer-specific synthetic lethality [26–32]. Recently, it was reported that the combination of an ATR inhibitor and a Chk1 inhibitor induces cancer-specific cell death in breast cancer cells and osteosarcoma cells [33], but there is no report about its effect on endometrial cancer cells. Therefore, in this study, we aimed to clarify the anti-tumor effect of an ATR inhibitor or an ATM inhibitor combined with DXR, CDDP, or
irradiation, and if the combination of the ATR inhibitor and the Chk1 inhibitor could induce DNA damage in endometrial cancer cells.

2. Results

2.1. The Effect of ATR Inhibitor or ATM Inhibitor Combined with DXR or CDDP in Endometrial Cancer Cells

We performed a cell viability assay to determine the half maximal inhibitory concentration (IC$_{50}$) value of VE822 (ATR inhibitor) and KU60019 (ATM inhibitor). Figure 1 shows the cell viability in various concentrations of the inhibitors. The IC$_{50}$ of VE822 was 1.5 µM and that of KU60019 was 20 µM.

Next, we performed immunoblotting to verify if the ATR or ATM pathway is activated by exposure to DXR or CDDP. The phosphorylation of Chk1 on Ser345 was considered as the index of ATR activation [34]. The phosphorylation of ATM on Ser1981 and that of Chk2 on Thr68 were considered as indices of ATM activation [35,36]. γH2AX was considered as the index of DNA double-strand breaks, and β-actin was the control. The exposure to both DXR and CDDP increased the expression of p-Chk1, p-ATM, p-Chk2, and p-H2AX. Moreover, the addition of the ATR inhibitor (10–1000 nM) decreased the expression of p-Chk1 (Figure 2a) and the addition of the ATM inhibitor (1–100 µM) decreased the expression of p-ATM and p-Chk2 (Figure 2b).
Figure 2. Cont.
Figure 2. DXR and CDDP activated both ATR/Chk1 and ATM/Chk2 pathways in HEC-6 endometrial cancer cells, which was canceled by each inhibitor. The medium was replaced with fresh medium containing (a) VE822 (0–1000 nM) or (b) KU60019 (0–100 µM) for 1 h before DXR (1 µM, 6 h) or CDDP (20 µM, 6 h) treatments. DXR, doxorubicin; CDDP, cisplatin. The lower histograms show the quantitative analyses of the intensities of the phosphoprotein bands from three independent experiments with SD indicated. A Western blot showing all the bands with all the molecular weight markers is in Supplemental Figure S1.

In light of these results, we then performed a clonogenic assay to examine the anti-tumor effect of the combination of a conventional chemotherapeutical drug and the ATR or ATM inhibitor. The combination of DXR (10–50 µM) or CDDP (100–500 nM) (Figure 3a) and VE822 (10–50 nM) or KU60019 (100–1000 nM) showed a remarkable enhancement of cell killing (Figure 3b).
Cancers 2019, 11, 1913 6 of 17

Figure 3. Both ATR and ATM inhibitors sensitize endometrial cancer cells to cell death. HEC-1B or HEC-6 cells were exposed to (a) DXR (10–50 μM) or (b) CDDP (100–500 nM) after incubation with VE822 (10–50 nM) or KU60019 (100–1000 nM) for 1 h, and cultured for 7–10 days. Colonies with ≥50 cells were counted and the cell survival percentage was calculated. Cells treated with dimethyl sulfoxide (DMSO) were used for normalization. DXR, doxorubicin; CDDP, cisplatin.

Furthermore, we performed flow cytometry to examine the cell cycle distribution after treatment with these chemotherapeutic drugs and inhibitors. As shown in Figure 4a, the combination of DXR and KU60019 remarkably increased the sub-G1 population to 24.7% compared to DXR alone (10.1%) or KU60019 alone (6.0%) on HEC-1B cells, and the combination of DXR and KU60019 increased the sub-G1 population to 14.0% compared to DXR alone (4.8%) or KU60019 (9.1%) alone on HEC-6 cells. When combining CDDP and VE822, there was a marked increase in the sub-G1 population to 29.8% compared to CDDP alone (4.0%) or VE822 alone (5.9%) on HEC-1B cells. On HEC-6 cells, interestingly, this combination increased the sub-G1 population to 20.3% compared to CDDP alone (4.5%) or VE822 alone (4.9%) (Figure 4b).
2.2. The Effect of ATR Inhibitor or ATM Inhibitor Combined with Irradiation in Endometrial Cancer Cells

We performed immunoblotting to examine the activation caused by irradiation and the inactivation with inhibitors of the ATR-Chk1 and ATM-Chk2 pathways. To examine the change over time in the activation of the pathway, we extracted proteins from cells that had been irradiated for periods ranging from 15 min to 72 h. Both the pathways were activated 2 h after irradiation (Figure 5a). Irradiation increased the expression of p-Chk1, p-ATM, p-Chk2, and p-H2AX. Moreover, adding the ATR inhibitor

Figure 4. Flow cytometric analysis of cell cycle in endometrial cancer cells treated with the combination of DNA-damaging agents and inhibitors. Cells were treated with the drugs for 48 or 72 h and cell cycle distribution was analyzed by flow cytometry. (a) DXR (50 nM) and KU60019 (10 µM) incubated for 48 h. (b) CDDP (500 nM) and VE822 (100 nM) incubated for 72 h. DXR, doxorubicin; CDDP, cisplatin.

The raw data is in Supplemental Figure S2.
VE822 (1 \( \mu \text{M} \)) decreased the expression of p-Chk1 (Figure 5b) and adding the ATM inhibitor KU60019 (10 \( \mu \text{M} \)) decreased the expression of p-ATM, p-Chk2, and p-H2AX (Figure 5c).

Figure 5. Cont.
Figure 5. Irradiation activated both ATR/Chk1 and ATM/Chk2 pathways in HEC-6 endometrial cancer cells, which was then canceled by each inhibitor. (a) Proteins were extracted from HEC-6 cells after irradiation for a period from 15 min to 72 h. The medium was replaced by fresh medium, and the inhibitor (b) VE822 (0–1000 nM) or (c) KU60019 (0–10 µM) was added for 1 h before irradiation (10 Gy). All proteins were extracted 2 h after irradiation. The lower histograms show the quantitative analyses of the intensities of the phosphoproteins bands from three independent experiments with SD indicated. A Western blot showing all the bands with all the molecular weight markers is in Supplemental Figure S1.

Next, we performed a clonogenic assay to examine the anti-tumor effect of the combination of irradiation and the inhibitors. Both VE822 (50 nM) and KU60019 (1 µM) enhanced the effect of irradiation (2–8 Gy) (Figure 6).
As the Chk1 inhibitor, and evaluated the synergy by calculating the combination index by the Talalay-Chou method. The two inhibitors are synergistically effective if the combination index is 1 or less. The combination index of VE822 and AZD7763 (50 nM) was 0.43 in HEC-1B cells, and 0.28 with HEC-6 cells, thus these inhibitors had a synergistic effect in both the cell lines (Figure 7).

Additionally, we performed a cell viability assay to examine the effect of the ATR inhibitor and a Chk1 inhibitor in endometrial cancer cells. Figure 7 shows the cell viability after exposure to different concentrations of the inhibitors. The IC$_{50}$ of VE822 was 1.5 μM and that of KU60019 was 20 μM. We used AZD7762 as the Chk1 inhibitor, and evaluated the synergy by calculating the combination index by the Talalay-Chou method. The two inhibitors are synergistically effective if the combination index is 1 or less. The combination index of VE822 and AZD7763 (50 nM) was 0.43 in HEC-1B cells, and 0.28 with HEC-6 cells, thus these inhibitors had a synergistic effect in both the cell lines (Figure 7).

Next, we performed immunoblotting and immunofluorescence to examine the DNA damage caused by the ATR and the CHK1 inhibitors. The combination of VE822 (1 μM) and AZD7762 (30–60 nM)
increased the expression of p-H2AX (Figure 8a). The results of the immunofluorescence experiment revealed that the combination of VE822 (1 µM) and AZD7762 (60 nM) induced nuclear accumulation of p-H2AX and BRCA1 (Figure 8b).

**Figure 8.** Evaluation of the effect of the combination of the ATR inhibitor and the Chk1 inhibitor by immunoblotting and immunofluorescence. (a) HEC-6 (upper figure) and HEC-1B (lower figure) were treated with VE822 (1 µM) and AZD7762 (30–60 nM) for 24 h before protein extraction. A Western blot showing all the bands with all the molecular weight markers is in Supplemental Figure S1. (b) HEC-1B cells were treated with VE822 (1 µM) and AZD7762 (60 nM) for 24 h before cell fixation and immunofluorescence analysis.

### 3. Discussion

In this study, we examined the anti-tumor effect of the inhibitors of the ATR-Chk1 or ATM-Chk2 pathway in endometrial cancer cells treated with DXR or CDDP, used as standard chemotherapeutic drugs in endometrial cancer treatment. As exposure to both DXR and CDDP increased the expression of p-H2AX in immunoblotting, it is assumed that these drugs induced DNA damage to endometrial cancer cells. Additionally, as both DXR and CDDP increased the expression of p-Chk1, p-ATM, and p-Chk2, it is possible that both ATR-Chk1 and ATM-Chk2 pathways were activated in response to the DNA damage.

The ATR inhibitor, VE822, decreased the expression of p-Chk1, which confirmed the inhibition of ATR activation. Similarly, the ATM inhibitor, KU60019, decreased the expression of p-ATM and
p-Chk2, confirming that ATM activation was inhibited. The expression of p-H2AX was decreased in the presence of KU60019, because H2AX was phosphorylated by activated ATM. VE822 (1000 nM) and KU60019 (100 µM) increased p-H2AX expression, because cells were injured by each single agent at these high concentrations. The combination of DXR and VE822 decreased p-ATM and p-CHk2 and the combination of DXR and KU60019 decreased p-Chk1. On the other hand, the combination of CDDP and VE822 did not decrease p-ATM or p-CHk2, and the combination of CDDP and KU60019 did not decrease p-CHk1. These differences may be due to the difference of the mechanism of DNA damage induced by DXR or CDDP, or due to the crosstalk between the ATR-Chk1 and ATM-Chk2 pathways.

The IC_{50} of VE822 was 1.5 µM and that of KU60019 was 20 µM, and these results demonstrated that VE822 inhibited the ATR-Chk1 pathway and KU60019 inhibited the ATM-Chk2 pathway at a concentration that did not affect cell viability. In the clonogenic assay, every combination of DXR or CDDP and VE822 (50 nM) or KU60019 (1 µM) showed a synergistic effect. The sub-G1 population of the combination group was increased in the cell cycle assay, suggesting that the synergy resulted from the induction of cell death.

Considering the results discussed above, we proved that the ATR inhibitor, VE822, inhibited the activation of the ATR-Chk1 pathway induced by DXR or CDDP and that the ATM inhibitor, KU60019, inhibited the activation of the ATM-Chk2 pathway induced by DXR or CDDP. Moreover, both the inhibitors enhanced the effect of DXR or CDDP in endometrial cancer cells. Further, we examined the effect of the combination of irradiation and these inhibitors. In immunoblotting, p-H2AX was increased in the irradiated group; therefore, DNA damage was considered to be induced in endometrial cancer cells; p-Chk1, p-ATM, and p-Chk2 were increased in the irradiated group, which indicated that the ATR-Chk1 and ATM-Chk2 pathways were activated in response to DNA damage. Additionally, p-Chk1 was decreased after the addition of VE822, and p-ATM and p-Chk2 followed the same trend after the addition of KU60019; therefore, we concluded that the ATR and ATM drugs inhibited the ATR-Chk1 and ATM-Chk2 pathways, respectively, which were activated by irradiation. In addition, the decrease in p-H2AX expression was due to inhibition of the activation of ATM by KU60019. Although VE822 did not decrease p-ATM or p-Chk2, KU60019 decreased p-Chk1. This may be the result of the crosstalk between the two pathways. In the clonogenic assay, the combination of irradiation and VE822 (50 nM) or KU60019 (1 µM) had a synergistic effect on cell killing. For the reason above, we concluded that both the inhibitors enhanced the effect of irradiation in endometrial cancer cells: the ATR inhibitor, VE822, inhibited the activation of the ATR-Chk1 pathway induced by irradiation; and the ATM inhibitor, KU60019, inhibited the activation of the ATM-Chk2 pathway, also caused by irradiation.

It is well known that various cancers harbor somatic mutations in the ATM-Chk2-p53 pathway. Thus, inhibiting the ATR-Chk1 pathway rather than the ATM-Chk2-p53 pathway may induce cancer-specific cell death, such as synthetic lethality. In this study, we examined the effect of the combination of the ATR inhibitor, VE822, and the Chk1 inhibitor, AZD7762. The results of the cell viability assay showed that there was a synergistic anti-tumor effect in endometrial cancer cells. Moreover, the immunoblotting analysis revealed that p-H2AX was increased, and in the immunofluorescence assay, p-H2AX and BRCA1 were found to be accumulated in the cell nuclei in the dual inhibition group. In endometrial cancer, Chk1 prevents unscheduled origin firing in concert with suppressing CDK, which is activated by oncogenic stress in a manner similar to that occurring in other cancer cells [33]. Thus, Chk1 inhibition induces excessive origin firing and elevates replication stress to increase single-strand DNA (ssDNA) in the stalled replication forks. In contrast, ATR inhibition facilitates the inhibition of replication protein A (RPA) supply, resulting in the collision of stalled replication forks and DNA double-strand breaks. Therefore, we believed that the combination of the ATR inhibitor and the Chk1 inhibitor induced DNA damage in endometrial cancer cells. As for the effect of the ATR inhibitor or the ATM inhibitor in endometrial cancer, a previous report showed that the ATR inhibitor ETP46464 enhanced the effect of CDDP in endometrial cancer cells, but the ATM inhibitor KU55933 did not [27]. While ETP46464 inhibited not only ATR, but also mammalian target of rapamycin (mTOR), DNA-dependent protein kinase (DNA-PK), phosphoinositide 3-kinases alpha
Cancers 2019, 11, 1913 13 of 17

(PI3Kα), and ATM [38–40], VE822 used in this study had higher selectivity to ATR, showing effects even at low concentrations. Similarly, KU60019 is an improved analog of KU55933 with demonstrated high selectivity to ATM and pronounced effect at low concentrations [41–43]. Thus, the enhancement of the anti-tumor effect of CDDP and DXR by VE822 and KU60019 was probably due to the high selectivity of these improved inhibitors. Therefore, adding these inhibitors to conventional chemotherapy can be a promising therapeutic option for endometrial cancer. It was reported previously that both ETP46464 and KU55933 enhanced the effect of irradiation, and that the combination of these two inhibitors more strongly enhanced this effect [25]. We did not examine the effect of the combination of the ATR inhibitor and the ATM inhibitor, but adding both VE822 and KU60019 may more strongly enhance the anti-tumor effect of irradiation.

In a previous publication, ATR mutation, often associated with poor prognosis, was identified in approximately 5% of the endometrial cancer cases. Moreover, ATR mutation was identified significantly in microsatellite instability-positive cases and as an independent factor of poor prognosis [44]. In these cases, some pathway other than ATR may compensate the DNA damage response. On the other hand, ATM expression was significantly decreased as the process of the carcinogenesis advanced in the endometrium [45]. Thus, a functional decline of ATM and ATR was associated with the process of the carcinogenesis or malignancy of endometrial cancer. Considering the biological feature of endometrial cancer in terms of failure of the DNA response pathway associated with carcinogenesis, DNA-damaging conventional therapy combined with molecular-targeted drugs of the DNA response pathway may induce new synthetic lethality.

The main limitation of our study was that we did investigate these effects in vivo. A previous publication demonstrated that VE822 combined with gemcitabine or irradiation suppressed tumor growth in a pancreatic cancer xenograft animal model, where the rate of oral administration was 60 mg/kg [39]. In addition, KU60019 combined with irradiation prolonged the overall survival of mice with glioma xenografts that received 10 µM (osmotic pumps) or 250 µM (conventional enhanced delivery) of the drug [43]. No adverse event was reported in both the studies. In our in vitro study, the concentrations which enhanced the effect of DXR, CDDP, or irradiation in the clonogenic assay were 10–50 nM (VE822) and 100–1000 nM (KU60019). These concentrations were significantly lower than those used in these previous reports, thus considered as feasible for safe administration in an in vivo setting. Further examination using endometrial cancer xenografts in vivo to evaluate the effectiveness or adverse effect is warranted.

The reason for the enhancement of the sensitivity to these DNA-damaging agents or irradiation is probably related to the DNA damage that remained unrepaired with these inhibitors; subsequently, cells deviated from the cell cycle checkpoints, resulting in cell death. HEC-1B cells have mutant p53 and HEC6 cells have wild-type p53. Considering that both ATR and ATM inhibitors enhanced the effect of the DNA-damaging agents and irradiation in both the cell lines, p53 pathway and other pathways seem to work cooperatively. Not only the status of p53, but also that of p53-independent pathways can be biomarkers of these inhibitors. More studies are needed to elucidate how the ATR-Chk1 pathway and the ATM-Chk2 pathway are used separately, and the type of crosstalk occurring between the two pathways. Moreover, additional studies are expected to reveal the most appropriate therapy to combine with these inhibitors in clinical applications (such as irradiation, DNA-damaging agents, or other molecular-targeted drugs) as well as the most suitable biomarker for such treatments.

4. Materials and Methods

4.1. Cell Culture and Reagents

The HEC-1B uterine endometrial cancer cell line was obtained from the American Type Culture Collection (Manassas, VA, USA) and HEC-6 cell line was established by Hiroyuki Kuramoto (Kanagawa Health Service Association, Japan). Both cell lines were cultured in Eagle’s minimal essential medium supplemented with 10% fetal bovine serum in a humidified incubator at 37 °C and 5% CO2. KU60019
(ATM inhibitor) and VE822 (ATR inhibitor) were purchased from Selleck (Houston, TX, USA). Both inhibitors were dissolved in DMSO (10 mM stock solutions) and stored at −80 °C.

4.2. Cell Viability Assay

Cells (2 × 10^4 cells/mL, 100 µL/well) were seeded in 96-well plates with medium and allowed to attach for 24 h. The medium was replaced with fresh medium containing KU60019 (0–10 µM) or VE822 (0–10 µM) for 1 h before doxorubicin (0–2.5 µM) or cisplatin (0–10 µM) treatment. Seventy-two hours later, 10 µL of Cell Count Kit-8 solution (Dojindo, Tokyo, Japan) was added to each well for 2 h for the methyl thiazolyl tetrazolium (MTT) assay. The change in absorbance at 450 nm was measured on a microplate reader (BioTek, Winooski, VT, USA); cells treated with DMSO were used for normalization. The experiment was repeated three times.

4.3. Clonogenic Assay

Cells were seeded in 6-well plates at a density of 1000 cells/well and allowed to attach for 24 h. Then, cells were incubated with KU60019 (0–1 µM) or VE822 (0–50 nM) for 1 h before adding doxorubicin (0–50 nM) or cisplatin (0–500 nM) or X-ray exposure (0–8 Gy) with Pantac HF350 (Shimadzu, Kyoto, Japan). After additional 7–10 days, i.e., the time required for a mean colony size of ≥50 cells, cells were fixed with methanol and stained with Giemsa. Colonies with ≥50 cells were counted manually. The cell survival percentage was calculated as the surviving fraction of cells in the presence of inhibitors for any given dose or concentration of the damaging agent divided by the surviving fraction of cells treated with DMSO alone.

4.4. Immunoblotting

Equal amounts of proteins were fractionated by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membranes were blocked and primary antibodies were added, followed by secondary antibodies. Signals were detected using an ImageQuant LAS 4000 Mini instrument (GE Healthcare, Wauwatosa, WI, USA).

HRP (horseradish peroxidase)-linked antibodies specific for ATR, phospho-ATR (Ser428), phosphor-Chk1 (Ser345), ATM, phospho-Chk2 (Thr68), phospho-H2AX (Ser139), and anti-mouse or anti-rabbit IgG were obtained from Cell Signaling Technology (Beverly, MA, USA). Antibodies specific for Chk1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), pATM from GeneTex (Irvine, CA, USA), Chk2 from Medical and Biological Laboratories (Nagoya, Japan), and β-actin from Sigma-Aldrich (St. Louis, MO, USA). Antibodies were used according to the manufacturers’ recommendations.

Protein bands were detected by the ECL Western Blot Detection Kit (GE Healthcare Life Sciences, Piscataway, NJ, USA).

Molecular weight markers were used and all gel images with the markers are shown in the Supplementary Figure S1.

4.5. Cell Cycle Analysis

Cells (2 × 10^5 cells/well) were seeded on 60 mm dishes. After 24 h of incubation, the medium was replaced with fresh medium containing various concentrations of the drugs for 72 h. Cells were collected by using trypsin and stained with propidium iodide (PI; 50 µg/mL) (Sigma-Aldrich) at 4 °C for 30 min in the dark. Cell cycle distribution was analyzed by flow cytometry on an Epics XL instrument (Beckman Coulter, Brea, CA, USA) using the Cell Quest Pro software v3.1. (BD Bioscience, Franklin Lakes, NJ, USA) according to the manufacturers’ recommendations. The experiment was repeated three times.
4.6. Statistical Analysis

The significance of the differences between the means was measured by one-tailed t-test. The values were expressed as means ± the standard error of the mean (SEM). A p-value < 0.05 was considered as statistically significant.

5. Conclusions

In this study, we investigated the anti-tumor effect of inhibitors of the ATR-Chk1 and ATM-Chk2 pathways in endometrial cancer cells. In particular, we evaluated the effect of the combination of an ATM or ATR inhibitor and conventional DNA-damaging therapy (doxorubicin, cisplatin, or irradiation) and found that both the inhibitors enhanced the cell sensitivity to the three conventional therapies. Moreover, the combination of the ATR and Chk1 inhibitors induced DNA damage in endometrial cancer cells and inhibited cell proliferation synergistically. Our results showed that DNA damage response pathway-targeting molecular therapies are promising treatment strategies for endometrial cancer.

Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/12/1913/s1, Figure S1: Western blot show all the bands with all the molecular weight markers. Figure S2: Flow cytometric analysis of cell cycle in endometrial cancer cells treated with the combination of DNA-damaging agents and inhibitors. Cells were treated with the drugs for 48 or 72 h and cell cycle distribution was analyzed by flow cytometry.

Author Contributions: Conceptualization, M.T. (Makoto Takeuchi), M.T. (Michihiro Tanikawa), K.N., and K.O.; methodology, M.T. (Makoto Takeuchi), M.T. (Michihiro Tanikawa), and K.N.; validation, M.T. (Makoto Takeuchi), K.N., and K.O.; formal analysis, M.T. (Makoto Takeuchi), K.N., and Y.K.; investigation, M.T. (Makoto Takeuchi), K.N., Y.K., S.O., C.A., K.S., and Y.M.; resources, M.T. (Makoto Takeuchi), M.T. (Michihiro Tanikawa), and H.K.; data curation, K.N.; writing—original draft preparation, M.T. (Makoto Takeuchi) and K.N.; writing—review and Editing, K.N.; supervision, K.O. and K.N.; project Administration, K.N., H.H., O.W.-H., K.O., T.A., Y.O., and T.F.; funding Acquisition, K.N. and K.O.

Funding: This work was supported by a Grant-in-Aid for Scientific Research C (grant numbers 15K10705 and 19K09834 to K.N.; 17K11268 to K.S.; and 18K09249 to K.O.); a Grant-in-Aid for Research Activity start-up (16H06757 to M.T.) from the Ministry of Education, Science and Culture, Japan. This research was also supported by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development, AMED (to K.O.).

Acknowledgments: We thank all colleagues for helpful discussions at the Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo.

Conflicts of Interest: K.O. received a research grant from Daiichi-Sankyo Co., Ltd. and lecture fee from Chugai Pharmaceutical Co., Ltd. and AstraZeneca Co., Ltd. K.N. received a research grant from MSD Co., Ltd. The other authors declare that they have no conflicts of interest.

References

1. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [CrossRef] [PubMed]
2. Bokhman, J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15, 10–17. [CrossRef]
3. Buring, J.E.; Bain, C.J.; Ehrmann, R.L. Conjugated estrogen use and risk of endometrial cancer. Am. J. Epidemiol. 1986, 124, 434–441. [CrossRef] [PubMed]
4. Brinton, L.A.; Lacey, J.V., Jr.; Sherman, M.E. Epidemiology of Gynecologic Cancers. Principles and Practice of Gynecologic Oncology, 4th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005; pp. 3–32.
5. Ko, E.M.; Walter, P.; Clark, L.; Jackson, A.; Franasiak, J.; Bolac, C.; Havrilesky, L.; Secord, A.A.; Moore, D.T.; Gehrig, P.A.; et al. The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: Prevalence and prognostic significance. Gynecol. Oncol. 2014, 133, 28–32. [CrossRef]
6. The Research Group for Population-Based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1998: Estimates based on data from 12 population-based cancer registries. Jpn. J. Clin. Oncol. 2003, 33, 241–245. [CrossRef]
7. Randall, M.E.; Filicaci, V.L.; Muss, H.; Spirtos, N.M.; Mannel, R.S.; Fowler, J.; Thigpen, J.T.; Benda, J.A. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy
in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2006, 24, 36–44. [CrossRef]

8. Colombo, N.; Preti, E.; Landoni, F.; Carinelli, S.; Colombo, A.; Marini, C.; Sessa, C.; ESMO Guidelines Working Group. Endometrial carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2011, 22 (Suppl. 6), vi35–vi39. [CrossRef]

9. Wright, J.D.; Medel, N.I.B.; Sehouli, J.; Fujiwara, K.; Herzog, T.J. Contemporary management of endometrial cancer. Lancet 2012, 379, 1352–1360. [CrossRef]

10. Morrow, C.P.; Bundy, B.N.; Kurman, R.J.; Creasman, W.T.; Heller, P.; Homesley, H.D.; Graham, J.E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol. Oncol. 1991, 40, 55–65. [CrossRef]

11. Creutzberg, C.L.; van Putten, W.L.; Koper, P.C.; Lybeert, M.L.; Jobsen, J.J.; Wárlam-Rodenhuis, C.C.; De Winter, K.A.; Lutgens, L.C.; van den Bergh, A.C.; van de Steen-Banasik, E.; et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000, 355, 1404–1411. [CrossRef]

12. Hosoya, N.; Miyagawa, K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014, 105, 370–388. [CrossRef] [PubMed]

13. Weber, A.M.; Ryan, A.J. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 2015, 149, 124–138. [CrossRef] [PubMed]

14. Kaelin, W.G., Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5, 689–698. [CrossRef] [PubMed]

15. Bouwman, P.; Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 2012, 12, 587–598. [CrossRef]

16. Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12, 801–817. [CrossRef] [PubMed]

17. Oda, K.; Okada, J.; Timmerman, L.; Rodriguez-Viciana, P.; Stokoe, D.; Shoji, K.; Taketani, Y.; Kuramoto, H.; Knight, Z.A.; Shokat, K.M.; et al. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008, 68, 8127–8136. [CrossRef]

18. Griffith, E.; Walker, S.; Martin, C.A.; Vagnarelli, P.; Stiff, T.; Vernay, B.; Al Sanna, N.; Saggar, A.; Hamel, B.; Earnshaw, W.C.; et al. Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling. Nat. Genet. 2008, 40, 232–236. [CrossRef]

19. Zhou, B.B.; Bartek, J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4, 216–225. [CrossRef]

20. Smith, J.; Tho, L.M.; Xu, N.; Gillespie, D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 2010, 108, 73–112.

21. Savitsky, K.; Bar-Shira, A.; Gilad, S.; Rotman, G.; Ziv, Y.; Vanagaite, L.; Tagle, D.A.; Smith, S.; Uziel, T.; Sfez, S.; et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995, 268, 1749–1753. [CrossRef]

22. Lavin, M.F.; Shiloh, Y. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol. 1997, 15, 177–202. [CrossRef]

23. Maréchal, A.; Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. 2013, 5, a012716. [CrossRef]

24. O’Connor, M.J. Targeting the DNA damage response in cancer. Mol. Cell 2015, 60, 547–560. [CrossRef]

25. Teng, P.N.; Bateman, N.W.; Darcy, K.M.; Hamilton, C.A.; Maxwell, G.L.; Bakkenist, C.J.; Conrads, T.P. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol. Oncol. 2015, 136, 554–561. [CrossRef]

26. Reaper, P.M.; Griffiths, M.R.; Long, J.M.; Charrier, J.-D.; MacCormick, S.; Charlton, P.A.; Golec, J.M.C.; Pollard, J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7, 428–430. [CrossRef]

27. Cremona, C.A.; Behrens, A. ATM signalling and cancer. Oncogene 2014, 33, 3351–3360. [CrossRef]
28. Biankin, A.V.; Waddell, N.; Kassahn, K.S.; Gingras, M.C.; Muthuswamy, L.B.; Johns, A.L.; Miller, D.K.; Wilson, P.J.; Patch, A.M.; Wu, J.; et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012, 491, 399–405. [CrossRef]

29. Angele, S.; Treilleux, I.; Bremond, A.; Taniere, P.; Hall, J. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. *Histopathology* 2003, 43, 347–353. [CrossRef]

30. Ai, L.; Vo, Q.N.; Zuo, C.; Li, L.; Ling, W.; Suen, J.Y.; Hanna, E.; Brown, K.D.; Fan, C.Y. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: Promoter hypermethylated with clinical correlation in 100 cases. *Cancer Epidemiol. Biomarkers Prev.* 2004, 13, 150–156. [CrossRef]

31. Kim, D.S.; Kim, M.J.; Lee, J.Y.; Lee, S.M.; Choi, J.E.; Lee, S.Y.; Park, J.Y. Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features. *Lung Cancer* 2009, 65, 247–250. [CrossRef]

32. Sullivan, A.; Yuille, M.; Repellin, C.; Reddy, A.; Reelfs, O.; Bell, A.; Dunne, B.; Gusterson, B.A.; Osin, P.; Farrell, P.J.; et al. Concomitant inactivation of p53 and Chk2 in breast cancer. *Oncogene* 2002, 21, 1316–1324. [CrossRef]

33. Sanjiv, K.; Hagenkort, A.; Calderon-Montano, J.M.; Koolmeister, T.; Reaper, P.M.; Mortusewicz, O.; Jacques, S.A.; Kuiper, R.V.; Schultz, N.; Scobie, M.; et al. Cancer-specific synthetic lethality between ATR and CHK1 kinase activities. *Cell Rep.* 2016, 14, 298–309. [CrossRef] [PubMed]

34. Zhao, H.; Piwnica-Worms, H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. *Mol. Cell Biol.* 2001, 21, 4129–4139. [CrossRef] [PubMed]

35. Bakkenist, C.J.; Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. *Nature* 2003, 421, 499–506. [CrossRef]

36. Lee, C.H.; Chung, J.H. The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. *J. Biol. Chem.* 2001, 276, 30537–30541. [CrossRef] [PubMed]

37. Chou, T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. *J. Biol. Chem.* 2001, 276, 440–446. [CrossRef] [PubMed]

38. Toledo, L.I.; Murga, M.; Zur, R.; Soria, R.; Rodriguez, A.; Martinez, S.; Oyarzabal, J.; Pastor, J.; Bischoff, J.R.; Fernandez-Capetillo, O. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. *Nat. Struct. Mol. Biol.* 2011, 18, 721–727. [CrossRef]

39. Fokas, E.; Prevo, R.; Pollard, J.R.; Reaper, P.M.; Charlton, P.A.; Cornelissen, B.; Vallis, K.A.; Hammond, E.M.; Oicina, M.M.; Gillies McKenna, W.; et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. *Cell Death Dis.* 2012, 3, e441. [CrossRef]

40. Fokas, E.; Prevo, R.; Hammond, E.M.; Brunner, T.B.; McKenna, W.G.; Muschel, R.J. Targeting ATR in DNA damage response and cancer therapeutics. *Cancer Treat. Rev.* 2014, 40, 109–117. [CrossRef]

41. Hickson, I.; Zhao, Y.; Richardson, C.J.; Green, S.J.; Martin, N.M.; Orr, A.J.; Reaper, P.M.; Jackson, S.P.; Curtin, N.J.; Smith, G.C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated ATM. *Cancer Res.* 2004, 64, 9152–9159. [CrossRef]

42. Golding, S.E.; Rosenberg, E.; Valerie, N.; Hussaini, I.; Frigerio, M.; Cockcroft, X.F.; Chong, W.Y.; Hummersone, S.; Rigoreau, L.; Mene, K.A.; et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. *Mol. Cancer Ther.* 2009, 8, 2894–2902. [CrossRef] [PubMed]

43. Biddlestone-Thorpe, L.; Sajjad, M.; Rosenberg, E.; Beckta, J.M.; Valerie, N.C.; Tokarz, M.; Adams, B.R.; Wagner, A.F.; Khalil, A.; Gilfor, D.; et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. *Clin. Cancer Res.* 2013, 19, 3189–3200. [CrossRef] [PubMed]

44. Zighelboim, I.; Schmidt, A.P.; Gao, F.; Thaker, P.H.; Powell, M.A.; Rader, J.S.; Gibb, R.K.; Mutch, D.G.; Goodfellow, P.J. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. *J. Clin. Oncol.* 2009, 27, 3091–3096. [CrossRef] [PubMed]

45. Shan, W.; Wang, C.; Zhang, Z.; Luo, X.; Ning, C.; Yu, Y.; Feng, Y.; Gu, C.; Chen, X. ATM may be a protective factor in endometrioid carcinogenesis with the progesterone pathway. *Tumour. Biol.* 2015, 36, 1529–1537. [CrossRef]